UNSPSC 51282923: Grepafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L1M1U2HC31, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo- but generally known as grepafloxacin, which bears US NIH Compound Identifier 72474. European Medicines Agency schedules Grepafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07965MIG.

UNSPSC 51282923 Grepafloxacin is a Commodity code for a specific fluoroquinolone antibiotic product. The recent state and local opportunities tagged under this code do not reflect procurement of Grepafloxacin itself; instead, they show purchases of related pharmaceutical products and harm-reduction supplies. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid (IFB) process. Seminole County, Florida issued an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. State and local buyers using this code classification are typically health departments and county health authorities acquiring pharmaceuticals and related medical supplies to support public health programs and emergency response initiatives.

The recent activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health contract, awarded in August 2026, indicates state-level health department engagement with pharmaceutical cooperative purchasing vehicles; the Seminole County opportunity from June 2026 reflects county-level procurement aligned with community health and harm-reduction missions. Neither opportunity involves actual Grepafloxacin procurement, suggesting the code may be misapplied by the issuing jurisdictions or the opportunities are tagged as related pharmaceutical products rather than the specific agent named in the code taxonomy. Vendors pursuing state and local pharmaceutical opportunities should verify the actual product specifications in RFQ and IFB notices rather than relying on UNSPSC code alone, as the mismatch between code label and purchase intent appears material in this category.